

Pharmacology and Therapeutics Advisory Committee

Objective advice to Pharmac

www.pharmac.govt.nz

Pharmacology and Therapeutics Advisory Committee Provisional Recommendations 14 & 15 May 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Mepolizumab for people with inadequately controlled COPD with an eosinophilic phenotype	Withheld*
Osilodrostat for people with endogenous Cushing's syndrome, subject to Special Authority criteria	High priority
Riociguat for people with CTEPH (Chronic Thromboembolic Pulmonary Hypertension), subject to Special Authority criteria	Low priority
Duloxetine hydrochloride for various conditions, with no funding restrictions	Cost neutral**
Anacaulase-bcdb for people with thermal burns (deep partial/ full thickness) for eschar removal, subject to access criteria	High priority
Risdiplam oral tablet for people Spinal Muscular Atrophy types 1-3, subject to existing Special Authority criteria for the liquid preparation	Cost neutral**
Durvalumab for people with muscle invasive bladder cancer for neoadjuvant and adjuvant treatment, subject to Special Authority criteria	High priority
Emicizumab for with people with moderate severity Haemophilia A with a clinically severe bleeding phenotype, subject to Special Authority criteria	High priority
Aflibercept 8mg pre-filled syringe for the treatment of visual impairment caused by subfoveal choroidal neovascularisation secondary to age-related macular degeneration and diabetic macular oedema, subject to Special Authority criteria	Cost neutral**

*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.

**Cost Neutral – The Committee has recommended this application be funded if the cost is neutral to the provision of the currently funded medicine(s), including the related health system costs

[More information about the agenda items considered at the recent Pharmacology and Therapeutics Advisory Committee meeting can be found on the Pharmac website](#)